161 related articles for article (PubMed ID: 22711372)
41. Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer.
Brugger W; Triller N; Blasinska-Morawiec M; Curescu S; Sakalauskas R; Manikhas GM; Mazieres J; Whittom R; Ward C; Mayne K; Trunzer K; Cappuzzo F
J Clin Oncol; 2011 Nov; 29(31):4113-20. PubMed ID: 21969500
[TBL] [Abstract][Full Text] [Related]
42. KRAS mutation: should we test for it, and does it matter?
Roberts PJ; Stinchcombe TE
J Clin Oncol; 2013 Mar; 31(8):1112-21. PubMed ID: 23401440
[TBL] [Abstract][Full Text] [Related]
43. Clinicopathological characteristics of patients with surgically resected lung cancer having tumours harboring anaplastic lymphoma kinase fusion protein.
Chen B; Jiang Z; Li C; Lu H
J Pak Med Assoc; 2020 Apr; 70(4):747-750. PubMed ID: 32296229
[TBL] [Abstract][Full Text] [Related]
44. p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category.
Walia R; Jain D; Madan K; Sharma MC; Mathur SR; Mohan A; Iyer VK; Kumar L
Indian J Med Res; 2017 Jul; 146(1):42-48. PubMed ID: 29168459
[TBL] [Abstract][Full Text] [Related]
45. Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Chung CH; Seeley EH; Roder H; Grigorieva J; Tsypin M; Roder J; Burtness BA; Argiris A; Forastiere AA; Gilbert J; Murphy B; Caprioli RM; Carbone DP; Cohen EE
Cancer Epidemiol Biomarkers Prev; 2010 Feb; 19(2):358-65. PubMed ID: 20086114
[TBL] [Abstract][Full Text] [Related]
46. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
[TBL] [Abstract][Full Text] [Related]
47. Clinical and pathological characteristics, outcome and mutational profiles regarding non-small-cell lung cancer related to wood-smoke exposure.
Arrieta O; Campos-Parra AD; Zuloaga C; Avilés A; Sánchez-Reyes R; Manríquez ME; Covián-Molina E; Martínez-Barrera L; Meneses A; Cardona A; Borbolla-Escoboza JR
J Thorac Oncol; 2012 Aug; 7(8):1228-34. PubMed ID: 22659961
[TBL] [Abstract][Full Text] [Related]
48. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
49. Are EUS-FNA and EBUS-TBNA specimens reliable for subtyping non-small cell lung cancer?
Tournoy KG; Carprieaux M; Deschepper E; van Meerbeeck JP; Praet M
Lung Cancer; 2012 Apr; 76(1):46-50. PubMed ID: 21945658
[TBL] [Abstract][Full Text] [Related]
50. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort.
Beau-Faller M; Ruppert AM; Voegeli AC; Neuville A; Meyer N; Guerin E; Legrain M; Mennecier B; Wihlm JM; Massard G; Quoix E; Oudet P; Gaub MP
J Thorac Oncol; 2008 Apr; 3(4):331-9. PubMed ID: 18379349
[TBL] [Abstract][Full Text] [Related]
51. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed.
Camidge DR; Kono SA; Lu X; Okuyama S; Barón AE; Oton AB; Davies AM; Varella-Garcia M; Franklin W; Doebele RC
J Thorac Oncol; 2011 Apr; 6(4):774-80. PubMed ID: 21336183
[TBL] [Abstract][Full Text] [Related]
52. Optimizing endobronchial ultrasound for molecular analysis. How many passes are needed?
Yarmus L; Akulian J; Gilbert C; Feller-Kopman D; Lee HJ; Zarogoulidis P; Lechtzin N; Ali SZ; Sathiyamoorthy V
Ann Am Thorac Soc; 2013 Dec; 10(6):636-43. PubMed ID: 24079724
[TBL] [Abstract][Full Text] [Related]
53. Lung cancers unrelated to smoking: characterized by single oncogene addiction?
Suda K; Tomizawa K; Yatabe Y; Mitsudomi T
Int J Clin Oncol; 2011 Aug; 16(4):294-305. PubMed ID: 21655907
[TBL] [Abstract][Full Text] [Related]
54. Bronchoscopic Re-biopsy for Mutational Analysis of Non-small Cell Lung Cancer.
Kirita K; Izumo T; Matsumoto Y; Hiraishi Y; Tsuchida T
Lung; 2016 Jun; 194(3):371-8. PubMed ID: 26951235
[TBL] [Abstract][Full Text] [Related]
55. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients.
Ulivi P; Romagnoli M; Chiadini E; Casoni GL; Capelli L; Gurioli C; Zoli W; Saragoni L; Dubini A; Tesei A; Amadori D; Poletti V
Int J Oncol; 2012 Jul; 41(1):147-52. PubMed ID: 22504767
[TBL] [Abstract][Full Text] [Related]
56. Treatment of older patients with advanced non-small cell lung cancer: A challenge.
Decoster L; Schallier D
J Geriatr Oncol; 2019 Jul; 10(4):528-533. PubMed ID: 30301660
[TBL] [Abstract][Full Text] [Related]
57. EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.
Thomas De Montpréville V; Ghigna MR; Lacroix L; Lemoine A; Besse B; Mercier O; Fadel É; Dorfmuller P; Le Chevalier T;
Pathol Res Pract; 2017 Jul; 213(7):793-798. PubMed ID: 28554746
[TBL] [Abstract][Full Text] [Related]
58. Pulmonary Non-Small Cell Carcinoma With Morphologic Features of Adenocarcinoma or "Non-Small Cell Carcinoma Favor Adenocarcinoma" in Cytologic Specimens Share Similar Clinical and Molecular Genetic Characteristics.
Hutchings D; Maleki Z; Rodriguez EF
Am J Clin Pathol; 2018 Apr; 149(6):514-521. PubMed ID: 29635384
[TBL] [Abstract][Full Text] [Related]
59. ALK-rearranged lung cancer: adenosquamous lung cancer masquerading as pure squamous carcinoma.
Chaft JE; Rekhtman N; Ladanyi M; Riely GJ
J Thorac Oncol; 2012 Apr; 7(4):768-9. PubMed ID: 22425930
[No Abstract] [Full Text] [Related]
60. Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Boldrini L; Alì G; Gisfredi S; Ursino S; Baldini E; Melfi F; Lucchi M; Comin CE; Maddau C; Tibaldi C; Camacci T; Servadio A; Mussi A; Fontanini G
Oncol Rep; 2009 Oct; 22(4):683-91. PubMed ID: 19724844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]